Literature DB >> 33249506

Levels of Soluble CD14 and Tumor Necrosis Factor Receptors 1 and 2 May Be Predictive of Death in Severe Coronavirus Disease 2019.

Emily R Bowman1, Cheryl M Ainslie Cameron2, Ann Avery3,4, Janelle Gabriel1, Aaren Kettelhut1, Michelle Hecker3,4, Claudia Ute Sontich3, Banumathi Tamilselvan2, Carmen N Nichols5, Brian Richardson2,5, Michael Cartwright5, Nicholas T Funderburg1, Mark J Cameron5.   

Abstract

People infected with severe acute respiratory syndrome coronavirus 2 display a wide range of illness, from asymptomatic infection to severe respiratory distress resulting in death. We measured serum biomarkers in uninfected individuals and in individuals with mild, moderate, or critical coronavirus disease 2019 (COVID-19) disease. Levels of monocyte activation (soluble CD14 and fatty acid-binding protein 4) and inflammation (tumor necrosis factor receptors 1 and 2 [TNFR1 and TNFR2]) were increased in COVID-19 individuals, regardless of disease severity. Among patients with critical disease, individuals who recovered from COVID-19 had lower levels of TNFR1 and TNFR2 at hospital admission compared to these levels in patients with critical disease who ultimately died.
© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  COVID-19; SARS-CoV-2; monocytes; tumor necrosis factor

Year:  2021        PMID: 33249506      PMCID: PMC7799002          DOI: 10.1093/infdis/jiaa744

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  10 in total

Review 1.  Immunosuppressant Therapies in COVID-19: Is the TNF Axis an Alternative?

Authors:  Yadira Palacios; Leslie Chavez-Galan
Journal:  Pharmaceuticals (Basel)       Date:  2022-05-17

2.  A single transcript for the prognosis of disease severity in COVID-19 patients.

Authors:  Hongxing Lei
Journal:  Sci Rep       Date:  2021-06-09       Impact factor: 4.379

Review 3.  TLRs in COVID-19: How they drive immunopathology and the rationale for modulation.

Authors:  F Linzee Mabrey; Eric D Morrell; Mark M Wurfel
Journal:  Innate Immun       Date:  2021-11-20       Impact factor: 2.951

4.  Plasma Soluble CD14 Subtype Levels Are Associated With Clinical Outcomes in Critically Ill Subjects With Coronavirus Disease 2019.

Authors:  F Linzee Mabrey; Eric D Morrell; Pavan K Bhatraju; Neha A Sathe; Sana S Sakr; Sharon K Sahi; T Eoin West; Carmen Mikacenic; Mark M Wurfel
Journal:  Crit Care Explor       Date:  2021-12-09

5.  Exploration of Potential Integrated Models of N6-Methyladenosine Immunity in Systemic Lupus Erythematosus by Bioinformatic Analyses.

Authors:  Xingwang Zhao; Lan Ge; Juan Wang; Zhiqiang Song; Bing Ni; Xiaochong He; Zhihua Ruan; Yi You
Journal:  Front Immunol       Date:  2022-02-07       Impact factor: 7.561

6.  Post-treatment with propofol inhibits inflammatory response in LPS-induced alveolar type II epithelial cells.

Authors:  Xilun Yang; Ling Ma
Journal:  Exp Ther Med       Date:  2022-01-31       Impact factor: 2.447

Review 7.  Immune system-related soluble mediators and COVID-19: basic mechanisms and clinical perspectives.

Authors:  Mohammad Sadegh Soltani-Zangbar; Forough Parhizkar; Mojtaba Abdollahi; Navid Shomali; Leili Aghebati-Maleki; Sima Shahmohammadi Farid; Leila Roshangar; Ata Mahmoodpoor; Mehdi Yousefi
Journal:  Cell Commun Signal       Date:  2022-08-29       Impact factor: 7.525

8.  Circulating tumor necrosis factor receptors are associated with mortality and disease severity in COVID-19 patients.

Authors:  Tomohito Gohda; Maki Murakoshi; Yusuke Suzuki; Makoto Hiki; Toshio Naito; Kazuhisa Takahashi; Yoko Tabe
Journal:  PLoS One       Date:  2022-10-11       Impact factor: 3.752

9.  Immune Signature Linked to COVID-19 Severity: A SARS-Score for Personalized Medicine.

Authors:  Jules Russick; Pierre-Emmanuel Foy; Nathalie Josseaume; Maxime Meylan; Nadine Ben Hamouda; Amos Kirilovsky; Carine El Sissy; Eric Tartour; David M Smadja; Alexandre Karras; Jean-Sébastien Hulot; Marine Livrozet; Antoine Fayol; Jean-Benoit Arlet; Jean-Luc Diehl; Marie-Agnès Dragon-Durey; Franck Pagès; Isabelle Cremer
Journal:  Front Immunol       Date:  2021-07-12       Impact factor: 7.561

10.  Plasma Markers of Disrupted Gut Permeability in Severe COVID-19 Patients.

Authors:  Leila B Giron; Harsh Dweep; Xiangfan Yin; Han Wang; Mohammad Damra; Aaron R Goldman; Nicole Gorman; Clovis S Palmer; Hsin-Yao Tang; Maliha W Shaikh; Christopher B Forsyth; Robert A Balk; Netanel F Zilberstein; Qin Liu; Andrew Kossenkov; Ali Keshavarzian; Alan Landay; Mohamed Abdel-Mohsen
Journal:  Front Immunol       Date:  2021-06-09       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.